According to our (Global Info Research) latest study, the global Targeted Therapy Drugs for Cancer market size was valued at US$ 124495 million in 2025 and is forecast to a readjusted size of US$ 196419 million by 2032 with a CAGR of 7.1% during review period.
In 2025, global Targeted Therapy Drugs for Cancer reached approximately 58.76 M Units, with an average global market price of around 2059 USD per Unit.
Targeted therapy drugs for cancer are anticancer medicines designed to specifically interfere with molecular targets—such as mutated genes, abnormal proteins, or dysregulated signaling pathways—that drive the growth, survival, or spread of cancer cells. These targets are typically involved in processes like cell proliferation, angiogenesis, DNA repair, or immune evasion, and are more active or uniquely altered in cancer cells compared with normal cells.
Unlike traditional chemotherapy, which broadly affects rapidly dividing cells, targeted cancer therapies act in a more precise and mechanism-driven manner, aiming to block cancer-specific biological processes while minimizing damage to healthy tissues. They include small-molecule drugs (often taken orally and acting inside cells) and biologic agents such as monoclonal antibodies (usually acting on cell-surface targets or extracellular ligands). Targeted therapies are commonly selected based on biomarker or genetic testing, making them a central component of precision oncology.
The upstream raw materials for Targeted Therapy Drugs for Cancer mainly include active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and excipients. Typical suppliers include Pfizer, Roche, Merck, and AstraZeneca. Downstream applications are primarily in oncology and rare disease treatments.
The single-line production capacity of Targeted Therapy Drugs for Cancer varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.
This report is a detailed and comprehensive analysis for global Targeted Therapy Drugs for Cancer market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Targeted Therapy Drugs for Cancer market size and forecasts, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2021-2032
Global Targeted Therapy Drugs for Cancer market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2021-2032
Global Targeted Therapy Drugs for Cancer market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2021-2032
Global Targeted Therapy Drugs for Cancer market shares of main players, shipments in revenue ($ Million), sales quantity (M Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Targeted Therapy Drugs for Cancer
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Targeted Therapy Drugs for Cancer market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Merck, Pfizer, AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Bayer, GSK, Daiichi Sankyo, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Targeted Therapy Drugs for Cancer market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Kinase Inhibitors
ADCs
Others
Market segment by Administration Route
Oral Drugs
Injectable Drugs
Others
Market segment by Molecular Properties
Small Molecule Drugs
Antibody Drugs
Others
Market segment by Application
Lung Cancer
Breast Cancer
Colorectal Cancer
Stomach Cancer
Liver Cancer
Others
Major players covered
Roche
Novartis
Merck
Pfizer
AstraZeneca
Johnson & Johnson
Bristol Myers Squibb
Bayer
GSK
Daiichi Sankyo
Amgen
Eli Lilly and Company
AbbVie
Sanofi
Takeda
Boehringer Ingelheim
Beigene, Ltd.
Jiangsu Hengrui Medicine
INNOVENT BIOLOGICS(SUZHOU)
Betta Pharmaceuticals
Remegen Co.,Ltd.
Shanghai Allist Pharmaceuticals
Innocare
Huiyu Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Targeted Therapy Drugs for Cancer product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Targeted Therapy Drugs for Cancer, with price, sales quantity, revenue, and global market share of Targeted Therapy Drugs for Cancer from 2021 to 2026.
Chapter 3, the Targeted Therapy Drugs for Cancer competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Targeted Therapy Drugs for Cancer breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Targeted Therapy Drugs for Cancer market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Targeted Therapy Drugs for Cancer.
Chapter 14 and 15, to describe Targeted Therapy Drugs for Cancer sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Targeted Therapy Drugs for Cancer. Industry analysis & Market Report on Targeted Therapy Drugs for Cancer is a syndicated market report, published as Global Targeted Therapy Drugs for Cancer Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Targeted Therapy Drugs for Cancer market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.